Trial · NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

NCT00385138, Phase 3, Terminated, The Medicines Company; results first posted 2014-04-21

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. Trials, record NCT00385138. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00385138

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
NCT number: NCT00385138
Status: Terminated
Phases: Phase 3
Enrollment: 5,364 participants, actual
Lead sponsor: The Medicines Company
Conditions: Atherosclerosis, Acute Coronary Syndrome (ACS)
Interventions: Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion
First posted: 2006-10-06
Last updated: 2014-05-05
Results first posted: 2014-04-21
Limitations and caveats: Discontinued per prespecified stopping rules after the 70% interim analyses was conducted indicating the trial was not likely not meet the goal of demonstrating superiority to clopidogrel administered as usual care. No safety issues were identified.

Source ClinicalTrials.gov

Registered outcomes20

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)	randomization through 48 hours post randomization	mITT population; (composite incidence)
Secondary	Incidence of All-cause Mortality or MI	randomization through 48 hours post randomization	mITT population
Secondary	Incidence of All-cause Mortality	randomization through 48 hours post randomization	mITT population
Secondary	Incidence of MI	randomization through 48 hours post randomization	mITT population
Secondary	Incidence of IDR	randomization through 48 hours post randomization	mITT population
Secondary	Incidence of Stent Thrombosis	randomization through 48 hours post randomization	mITT population
Secondary	Incidence of Stroke	randomization through 48 hours post randomization	mITT
Secondary	Incidence of All-cause Mortality	randomization through 1 year post randomization	mITT population
Secondary	Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis]	During index PCI	mITT population A patient could have multiple procedural events.
Secondary	Incidence of GUSTO Severe / Life-threatening	randomization through 48 hours post randomization	Major bleeding (non-CABG-related) - Safety population

1 to 10 of 20Source ClinicalTrials.gov

See all 20 registered outcomes

Outcomes20

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)	randomization through 48 hours post randomization	mITT population, based on available data	participants	NUMBER
SECONDARY	Incidence of All-cause Mortality or MI	randomization through 48 hours post randomization	mITT population, based on available data	participants	NUMBER
SECONDARY	Incidence of All-cause Mortality	randomization through 48 hours post randomization	mITT population, based on available data	participants	NUMBER
SECONDARY	Incidence of MI	randomization through 48 hours post randomization	mITT population, based on available data	participants	NUMBER
SECONDARY	Incidence of IDR	randomization through 48 hours post randomization	mITT population, based on available data	participants	NUMBER
SECONDARY	Incidence of Stent Thrombosis	randomization through 48 hours post randomization	mITT population, based on available data	participants	NUMBER
SECONDARY	Incidence of Stroke	randomization through 48 hours post randomization	mITT population, based on available data	participants	NUMBER
SECONDARY	Incidence of All-cause Mortality	randomization through 1 year post randomization	mITT population, based on available data	participants	NUMBER
SECONDARY	Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis]	During index PCI	mITT population, based on available data	participants	NUMBER
SECONDARY	Incidence of GUSTO Severe / Life-threatening	randomization through 48 hours post randomization	Safety population	participants	NUMBER

1 to 10 of 20Source ClinicalTrials.gov

See all 20 outcomes

Results by group40

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)	Cangrelor	185	participants
Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)	Clopidogrel	210	participants
Incidence of All-cause Mortality or MI	Cangrelor	180	participants
Incidence of All-cause Mortality or MI	Clopidogrel	204	participants
Incidence of All-cause Mortality	Cangrelor	6	participants
Incidence of All-cause Mortality	Clopidogrel	18	participants
Incidence of MI	Cangrelor	177	participants
Incidence of MI	Clopidogrel	191	participants
Incidence of IDR	Cangrelor	19	participants
Incidence of IDR	Clopidogrel	24	participants

1 to 10 of 40Source ClinicalTrials.gov

See all 40 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Cangrelor	2,695
Overall Study	STARTED	Clopidogrel	2,669
Overall Study	Intent-to-treat (ITT)	Cangrelor	2,693
Overall Study	Intent-to-treat (ITT)	Clopidogrel	2,669
Overall Study	Modified Intent-to-treat (mITT)	Cangrelor	2,656
Overall Study	Modified Intent-to-treat (mITT)	Clopidogrel	2,645
Overall Study	Safety Population	Cangrelor	2,662
Overall Study	Safety Population	Clopidogrel	2,650
Overall Study	COMPLETED	Cangrelor	2,665
Overall Study	COMPLETED	Clopidogrel	2,641

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events150

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	back pain	Musculoskeletal and connective tissue disorders	Cangrelor	91	2,662
other	back pain	Musculoskeletal and connective tissue disorders	Clopidogrel	85	2,650
other	chest pain	General disorders	Cangrelor	73	2,662
other	chest pain	General disorders	Clopidogrel	69	2,650
other	nausea	Gastrointestinal disorders	Cangrelor	71	2,662
other	nausea	Gastrointestinal disorders	Clopidogrel	66	2,650
other	headache	Nervous system disorders	Cangrelor	60	2,662
other	headache	Nervous system disorders	Clopidogrel	68	2,650
other	hypotension	Vascular disorders	Cangrelor	43	2,662
other	hypotension	Vascular disorders	Clopidogrel	38	2,650

1 to 10 of 150Source ClinicalTrials.gov

See all 150 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Cangrelor
Total, all-cause mortality	Clopidogrel
Total, other adverse events	Cangrelor	596	2,662
Total, other adverse events	Clopidogrel	530	2,650
Total, serious adverse events	Cangrelor	48	2,662
Total, serious adverse events	Clopidogrel	55	2,650

Source ClinicalTrials.gov

Papers8

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
19915222	RESULT	PubMed
22305835	DERIVED	PubMed
27902833	DERIVED	PubMed
28382371	DERIVED	PubMed
28988157	DERIVED	PubMed
29632238	DERIVED	PubMed
35196863	DERIVED	PubMed
38551015	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons21

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Cangrelor vs Clopidogrel: Incidence of All-cause Mortality or MI	Trial comparisons
Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding	Trial comparisons
Cangrelor vs Clopidogrel: Incidence of MI	Trial comparisons
Cangrelor vs Clopidogrel: Incidence of All-cause Mortality	Trial comparisons
Cangrelor vs Clopidogrel: Incidence of Stent Thrombosis	Trial comparisons
Cangrelor vs Clopidogrel: Incidence of Stroke	Trial comparisons
Cangrelor vs Clopidogrel: Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major	Trial comparisons
Cangrelor vs Clopidogrel: Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis]	Trial comparisons
Cangrelor vs Clopidogrel: Incidence of Stent Thrombosis	Trial comparisons
Cangrelor vs Clopidogrel: Incidence of All-cause Mortality, MI, or IDR	Trial comparisons

1 to 10 of 21

See all 21 trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00385138

GET https://conductscience.org/api/trials/v1/NCT00385138/results?page=2

API reference For AI assistants